EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

EyeGate Pharmaceuticals (NASDAQ:EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced top-line results from a Phase 2b study of EGP-437 combination product for pain and inflammation in patients having undergone cataract surgery.

As quoted in the press release:

“The efficacy results for the absence of inflammatory cells in the EGP-437 treatment group met our expectations, but the vehicle group response was better than anticipated. The magnitude of reduction for EGP-437 compares favorably with the historical data from studies of other anti-inflammatory products, which we believe is an encouraging sign,” said Randall Olson MD, strategic advisor to EyeGate.

Click here to read the full press release.